GLP-1 medications like Ozempic and Wegovy have revolutionized weight loss and diabetes treatment.
But one big issue keeps many people from using them: they must be injected.
That could soon change. Pharmaceutical companies are racing to bring GLP-1 pills to market, and some promising candidates are already in late-stage trials.
So how close are we to an Ozempic-style weight loss pill—and how well will it really work?
Here’s what the future of GLP-1 pills looks like—and what this means if you’re managing weight or diabetes.
Jump to:
Why a Pill Could Change Everything
Injectable medications come with a list of obstacles—needle fear, storage challenges, and high prices.
“Many patients prefer pills to injections,” says Dr. Christoph Buettner, chief of endocrinology at Rutgers Robert Wood Johnson Medical School.
Pills are also logistically easier.
“Injectables need refrigeration and auto-injector pens, which makes them harder for pharmacies to keep in stock,” says Christy Gallagher, associate director for Research and Policy at the STOP Obesity Alliance.
“Overall, a pill would be easier for patients to access,” she explains.
Oral GLP-1 drugs could also serve different use cases, including as a starting point for those hesitant about injections, or as a maintenance med after major weight loss.
But creating an effective GLP-1 pill hasn’t been easy.
“They are less effective than injectables, are easily degraded, and have decreased absorption from the gut,” says Dr. Hanna Lee, an endocrinologist at Lenox Hill Hospital.
What’s Already Available?
Right now, the only FDA-approved oral GLP-1 drug is Rybelsus.
Approved in 2019, it’s a version of semaglutide—the same ingredient in Ozempic—but it’s aimed at managing Type 2 diabetes, not obesity.
“It is indicated for the management of diabetes, not obesity,” explains Dr. Kais Rona, bariatric surgeon at MemorialCare Surgical Weight Loss Center.
Users of Rybelsus have experienced about 8 pounds of weight loss over six months, according to its own clinical data.
That pales in comparison to injectable semaglutide, which can lead to 10 to 17 percent total body weight loss.
Compare that to meds like Zepbound or Mounjaro, which may cause up to 21 percent weight loss, according to 2024 data published by JAMA.
So while Rybelsus exists, its impact is smaller, especially for weight loss specifically.
Other Weight Loss Pills on the Market
Although medications like Contrave, Qsymia, and Orlistat are not GLP-1 drugs, they’re FDA-approved and available now.
Each works through a different mechanism, whether by suppressing appetite or reducing fat absorption.
However, their effectiveness tends to stay within a 5 to 10 percent range in total body weight loss.
Plus, many users report side effects like nausea, GI issues, or insomnia.
What’s Coming Next?
Several companies are investing in GLP-1 pills, but the standout is orforglipron, developed by Eli Lilly—the makers of Mounjaro and Zepbound.
In a phase 3 trial, orforglipron delivered an average 12.4 percent weight loss—over 27 pounds—compared to just 2.2 pounds in those taking placebo.
That’s remarkable progress for a pill and much closer to injectable benefits.
Other players in the game include Viking Therapeutics, Terns Pharmaceuticals, and Structure Therapeutics, all advancing pills that activate the GLP-1 pathway.
Pfizer, however, recently shut down its oral GLP-1 candidate, danuglipron, after it raised concerns around liver toxicity.
Meanwhile, early research is even exploring ways to target four hormonal receptors at once—a massive leap, though it’s far off and still in early trials.
When Can You Expect GLP-1 Pills?
If everything stays on track, experts believe orforglipron could hit the shelves as early as late 2025.
Dr. Buettner describes that timeline as “months to a year.”
That would mark a major shift in accessibility for those dealing with obesity, which Dr. Lee calls “a global public health problem.”
“We must continue to develop effective, safe weight loss medications and ensure affordable accessibility,” she emphasizes.
The Bottom Line
Oral GLP-1 medications could offer life-changing benefits for millions—but only if they match the effectiveness of injectables without the same barriers.
For now, Rybelsus is an option primarily for diabetes control, and a range of non-GLP-1 pills exist with varying success.
But with orforglipron and other new options in the pipeline, the GLP-1 pill revolution might arrive sooner than you think.
